These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 32901897

  • 1. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N, Takahashi F, Tomomatsu K, Obayashi S, Takeuchi T, Takihara T, Hayama N, Oguma T, Aoki T, Asano K.
    Tokai J Exp Clin Med; 2020 Sep 20; 45(3):113-116. PubMed ID: 32901897
    [Abstract] [Full Text] [Related]

  • 2. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
    Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM, Perng RP, Chih-Hsin Yang J.
    J Thorac Oncol; 2015 May 20; 10(5):793-799. PubMed ID: 25668120
    [Abstract] [Full Text] [Related]

  • 3. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
    Watanabe M, Oizumi S, Kiuchi S, Yamada N, Yokouchi H, Fukumoto S, Harada M.
    Intern Med; 2018 Apr 01; 57(7):993-996. PubMed ID: 29225262
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, Calles A, Cedrés S, Viñolas N, Isla D, Palmero R, Sereno M, Diaz V, Juan O, Marsé R, Martorell PM, Sánchez Torres JM, Study Group for the Uncommon EGFR Mutations in Spain.
    Clin Lung Cancer; 2020 Sep 01; 21(5):428-436.e2. PubMed ID: 32461037
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
    Tanizaki J, Banno E, Togashi Y, Hayashi H, Sakai K, Takeda M, Kaneda H, Nishio K, Nakagawa K.
    Lung Cancer; 2016 Nov 01; 101():11-15. PubMed ID: 27794398
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
    Li T, Wang S, Ying J, Wang Y, Hu X, Hao X, Xu Z, Xing P, Li J.
    Thorac Cancer; 2021 Nov 01; 12(21):2924-2932. PubMed ID: 34549528
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    Han C, Ding X, Li M, Luo N, Qi Y, Wang C.
    J Cancer Res Clin Oncol; 2022 May 01; 148(5):1265-1268. PubMed ID: 35230510
    [Abstract] [Full Text] [Related]

  • 19. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K, Yu X, Wang H, Huang Z, Xu Y, Gong L, Fan Y.
    Cancer Chemother Pharmacol; 2017 Dec 01; 80(6):1179-1187. PubMed ID: 29063948
    [Abstract] [Full Text] [Related]

  • 20. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB.
    Oncologist; 2021 Apr 01; 26(4):281-287. PubMed ID: 32969527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.